The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA approves 1st RSV vaccine for adults under 60
